ECDC is organising a physical workshop between 16 and 18 April 2024 with national experts to develop a public health guidance to support the assessment of the risk of locally-acquired Aedes-borne viral diseases in the EU/EEA.
Risks of an adverse event following influenza vaccination are far less common than complications related to influenza itself, and the adverse events are generally localised and mild.
Information on autochthonous vectorial transmission of dengue in mainland EU/EEA, including location, period, number of cases, virus serotype and mode of transmission.
This document assesses the risk associated with the dissemination of carbapenemase-producing hypervirulent Klebsiella pneumoniae (hvKp) of sequence type (ST) 23 and other STs in the European Union/European Economic Area (EU/EEA).
ECDC initiated a survey of EU/EEA countries to evaluate preparedness planning and risk mitigation initiatives implemented at the country level for people exposed to highly pathogenic avian influenza virus A(H5N1).
The aim of this survey was to review the expertise, capabilities and capacities for detection and characterisation of avian and other zoonotic influenza viruses in national influenza reference laboratories in the European Union/European Economic Area (EU/EEA), in members of the European Reference Laboratories for influenza (ERLINet), and in EU Enlargement policy countries.
The Global Influenza Surveillance and Response System (GISRS), led by WHO, is used for the international virological and epidemiological surveillance of human influenza.
Seasonal influenza is a vaccine-preventable disease and annual influenza vaccination is the most effective way to prevent influenza. ECDC continues to emphasise that all Europeans who are recommended to have the influenza vaccine should get vaccinated.